{
    "symbol": "CRMD",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-30 12:51:02",
    "content": "  These statements are subject to certain risks and uncertainties and include but are not limited to any of the following: any statements, other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects, including its clinical development program, manufacturing activities, and NDA approval for DefenCath in the U.S. or other product candidates, future financial position, future revenues, and projected costs, and potential market acceptance of DefenCath or other product candidates."
}